Dr. Hafrun Fridriksdottir
Executive Vice President, Global R&D
Dr. Fridriksdottir became Executive Vice President, Global R&D in November 2017.
From February 2017 to November 2017, she served as Executive Vice President, President of Global Generics R&D, after serving as Senior Vice President and President of Global Generics R&D from 2016.
Prior to joining Teva, from 2015 to 2016, Dr. Fridriksdottir served as Senior Vice President and President of Global Generics R&D in Allergan plc.
From 2002 to 2015, she held positions of increasing responsibility within the Actavis Group, including Senior Vice President, R&D.
From 1997 to 2002, Dr. Fridriksdottir served as Divisional Manager of Development at Omega Pharma, until its merger with Actavis. Dr. Fridriksdottir received an MS degree in pharmacy and a Ph.D. in physical pharmacy from the University of Iceland.
Kåre Schultz
President and Chief Executive Officer, Member of the Board of Directors
Richard Daniell
Executive Vice President, European Commercial
Dr. Sven Dethlefs
Executive Vice President, North America Commercial
Eric Drapé
Executive Vice President, Global Operations
Galia Inbar
Executive Vice President, Chief Human Resources Officer and Head of Global Communications and Brand
Eli Kalif
Executive Vice President, Chief Financial Officer (CFO)
Mark Sabag
Executive Vice President, International Markets Commercial
Eli Shani
Executive Vice President, Global Marketing and Portfolio
David M. Stark
Executive Vice President, Chief Legal Officer
Nir Baron
Senior Vice President, Chief Internal Auditor
Lori Queisser
Sr. Vice President & Global Compliance Officer
